相关实验视频

Updated: Jul 26, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

十年视觉恢复和变化在视缩后的变化肠内拉尼比祖马布用于斑点新血管化在病理性迷眼症中

Ryo Sakata¹, Manabu Miyata¹, Sotaro Ooto¹

¹Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and.

Retina (Philadelphia, Pa.)

|June 20, 2023

概括

在近视性黄斑新血管化患者中,经过单次拉尼比祖马布注射和预先注射后,长期视力敏度维持了10年. 大多数眼睛的胆管缩进展,但没有出现药物并发症.

科学领域:

眼科医生眼科眼科
视网膜疾病视网膜疾病
医疗视网膜医学视网膜

背景情况:

病态近视可以导致近视性黄斑新血管化 (MNV),这是视力丧失的重要原因.
内抗VEGF疗法是对MNV的常见治疗方法,但长期结果需要进一步调查.

研究的目的:

为了评估10年的视觉结果和胆管缩的进展后,初始静脉内拉尼比祖马布注射和随后的pro re nata (PRN) 治疗方案近视性MNV.
确定影响10年最佳校正视敏度 (BCVA) 的因素.

主要方法:

一项追溯观察性研究,对26个经过治疗的眼睛进行了近视MNV.
患者接受了最初的静脉内拉尼比祖马布注射,随后在10年内接受了拉尼比祖马布和/或阿弗利塞普特的PRN疗法.
评估包括使用META-PM研究类别的BCVA和胆管缩的变化.

主要成果:

平均BCVA从基线 (0.36 ± 0.39) 到10年 (0.39 ± 0.36) 保持稳定,最初在1年后有所改善 (P = 0.002).
在10年后,没有眼睛的BCVA为20/200或更差. 基线BCVA与10年BCVA有显著的相关性 (P = 0.01,r = 0.47).
胆管缩 (META-PM研究类别) 在60%的眼睛中进展,特别是在老年患者中. 没有观察到药物诱导的并发症.

结论:

一次静脉内射拉尼比祖马布注射,然后进行PRN疗法,在近视MNV患者中有效维持了BCVA10年,没有严重的并发症.
胆管缩的进展很常见,这突出了早期诊断和治疗的重要性,以保持长期的视觉功能.

更多相关视频

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...